1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease, 2001. http://www.goldcopd.org/Guidelines/guidelines-resources.html
2. Vanfleteren LE, Franssen FM, Wesseling G, Wouters EF. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir Med 2012; 106 (6): 871–4.
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available from: http://www.goldcopd.org/
4. Российский статистический ежегодник. М., 2011. http://www.gks.ru/bgd/regl/b11_34/IssWWW.exe/Stg/d01/01-01.htm
5. World Health Organization 2011 Reprinted 2011 WHO Library Cataloguing-in-Publication Data Global status report on noncommunicable diseases 2010.
6. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–504.
7. NMH/MND/CPM/13.1 Global alliance against chronic respiratory diseases (GARD) 7th General Meeting, 9–10 July 2012, St. Petersburg, Russia http://www.who.int/gard/publications/GARDGMReportStPetersburg2012.pdf
8. Клинические рекомендации. Хроническая обструктивная болезнь легких. 2-е изд., испр. и доп. Под ред. А.Г. Чучалина, М.: ИД «Атмосфера», 2007.
9. Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) – why and what? Clin Respir J 2012; 6: 208–14.
10. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645–8.
11. Vestbo J, Edwards L, Scanlon P et al. Changes in Forced Expiratory Volume in 1 Second over Time in COPD. N Engl J Med 2011; 365: 1184–92.
12. Agusti A, Calverley P, Celli B et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122–36.
13. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006. Available from: http://www.goldcopd.org/
14. Gruffydd-Jones K. GOLD guidelines 2011: what are the implications for primary care? Prim Care Respir J 2012; 21 (4): 437–41.
15. Jones PW. Health status and the spiral of decline. COPD 2009; 6: 59–63.
16. Hurst JR, Vestbo J, Anzueto A et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–38.
17. Holguin F, Folch E, Redd SC, Mannino DM. Co-morbidity and mortality in COPD related hospitalisations in the United States 1979 to 2001. Chest 2005; 128: 2005–11.
18. Wang PS, Avorn J, Brookhart MA et al. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension 2005; 46 (2): 273–9.
19. Druss BG, Marcus SC, Olfson M, Pincus HA. The most expensive medical conditions in America. Health Aff (Millwood) 2002; 21: 105–11.
20. Чазова И.Е., Чучалин А.Г., Зыков К.А., Ратова Л.Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. 2013; 10 (1): 5–35.
21. Bestall JC, Paul EA, Garrod R et al. Usefulness of the Medical Research Council (MRC) dyspnea scale as measure of dusability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–6.
22. Dodd JW, Hogg L, Nolan J et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicenter, prospective study. Thorax 2011; 66: 425–9.
23. Johannessen A, Nilsen R, Storeb M et al. Comparison of 2011 and 2007 gold guidelines for predicting mortality and hospitalization. Am J Respir Crit Care Med. Published on 05-April-2013 as 10.1164/rccm.201212-2276OC
24. Lange P, Marott JL, Vestbo J et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new gold classification: A study of the general population. Am J Respir Crit Care Med 2012; 186: 975–81.
25. Soriano JB, Alfageme I, Almagro P et al. Distribution and prognostic validity of the new gold grading classification. Chest 2012. E-published ahead of print 29 Nov 2012.
26. Reda AA, Kotz D, Kocks JW et al. Reliability and validity of the clinical COPD questionniare and chronic respiratory questionnaire. Respir Med 2010; 104: 1675–82.
27. Agusti A, Hurd S, Jones P et al. Frequently asked questions about the gold 2011 assessment proposal of COPD. A comparative analysis of four different cohorts. ERJ Express. Published on May 3, 2013 as doi: 10.1183/09031936.00036513
28. Miravitlles M, Soler-Cataluña JJ, Calle M et al. Spanish COPD guidelines (GesEPOC). Pharmacological treatment of stable COPD. Arch Bronconeumol 2012; 48: 247–57.

К.А.Зыков1, Е.И.Соколов2

1. Лаборатория пульмонологии НИМСИ;
2. Кафедра факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ